| Revenue growth | FY26 Group revenue grew 24% YoY to ₹1,646 Cr. |
|---|---|
| Margins | EBITDA margins reached 27.2% in Q4FY26; FY26 organic margin at 25.9%. |
| Demand visibility | Sustainable demand driven by network expansion into Tier 3 cities. |
| Management confidence | High; emphasizing 'year of compounding' and meaningful margin expansion. |
Growth
FY26 Group Revenue: ₹1,646 Cr (+24%); PAT: ₹191 Cr (+31%). Q4FY26 Organic revenue grew 15% on 9.3% patient volume growth.
Outlook
Targeting mid-teen revenue CAGR (FY23-FY26); aim for pre-Covid margin profiles and expanding to ~800 towns via 'Micro Market Strategy'.
Risks
Integration of Core Diagnostics (Q1FY27 completion); potential impact from new labor codes (₹8.3 Cr exceptional item in FY26).
Earnings Call filed with BSE, NSE: METROPOLIS. Summary written with AI assistance from the document.
Metropolis Healthcare Ltd: key numbers
- Share price
- ₹541.45
- Market cap
- ₹11,233 Cr
- Revenue (annual)
- ₹1,646 Cr
- Net profit (annual)
- ₹190.0 Cr
- P/E (TTM)
- 55.7×Sector 53.1×
- Promoter holding
- 48.86%-0.01% QoQ
- FII holding
- 11.03%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Metropolis Healthcare Ltd
All →Metropolis Healthcare Employee Stock Options
Metropolis Healthcare allotted 66,312 equity shares to employees under its RSU Plan, 2020. This exercise follows the vesting of RSUs previously granted to staff.
Metropolis Healthcare Merger & Restructuring Worth ₹1.26 Cr
Metropolis Healthcare's subsidiary MQSPL will issue shares to Medsource and Dr. Puneet Kumar Nigam for ₹1.26 Crore, diluting MHL's stake to 54.90% through this strategic restructuring.
- Value
- ₹1.26 Cr
Metropolis Healthcare Capital Structure Change
Franklin Templeton Mutual Fund acquired 7,42,409 Metropolis Healthcare shares via open market, raising its stake to 5.10%. No transaction value was disclosed in the filing.
Metropolis Healthcare Merger & Restructuring Worth ₹1.25 Cr
Metropolis Healthcare transferred its External Quality Assessment Services Division to subsidiary MQSPL for ₹1.25 Crore. The transfer was executed via a slump sale.
- Value
- ₹1.25 Cr
Metropolis Healthcare Merger & Restructuring Worth ₹0.01 Cr
Metropolis Healthcare's subsidiary, MQSPL, will issue 10,000 Optionally Convertible Redeemable Preference Shares (OCRPS) to Dr. Puneet Kumar Nigam. Post-conversion, MQSPL will remain a subsidiary.
- Value
- ₹0.01 Cr
Metropolis Healthcare Annual General Meeting
Metropolis Healthcare held its 26th Annual General Meeting on August 18, 2026. Shareholders reviewed financial statements and confirmed previous interim dividend payments.